Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0843
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib ; day:26 ; month:3 ; year:2016 ; pages:1-18
Cancer chemotherapy and pharmacology ; (26.3.2016), 1-18
- Urheber
-
Bryan, Jeffrey C.
- Beteiligte Personen und Organisationen
-
Verstovsek, Srdan
SpringerLink (Online service)
- DOI
-
10.1007/s00280-016-3012-z
- URN
-
urn:nbn:de:1111-2016033029073
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:57 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Bryan, Jeffrey C.
- Verstovsek, Srdan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
JAK2 Negative Polycythemia Vera
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
JAK2 Negative Polycythemia Vera
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study
Ruxolitinib Adherence in Myelofibrosis and Polycythemia Vera: the “RAMP” Italian multicenter prospective study
Management of myelofibrosis after ruxolitinib failure
Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies
Population pharmacokinetics of fedratinib in patients with myelofibrosis, polycythemia vera, and essential thrombocythemia
Resolution of thrombocytopenia, but not polycythemia after ruxolitinib for polycythemia vera with detectable mutation in the exon 12 of the JAK2 gene
JAK2 Negative Polycythemia Vera
Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice
Primary myelofibrosis associated glomerulopathy: significant improvement after therapy with ruxolitinib
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea
Ruxolitinib therapy for myelofibrosis in Austria : Consensus on therapy management
Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia